LEXINGTON, Mass., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop next generation targeted drug candidates for the treatment of human cancers, today announced the appointment of Jaye Viner, M.D. as Chief Medical Officer and Executive Vice President. Dr. Viner will be responsible for the leadership of Curis' clinical development strategy and efforts to further the development of its pipeline of proprietary drug candidates. In addition to Dr. Viner's appointment, Curis also announced the appointment of Tania Chander, Pharm.D. as Vice President of Product Development. Dr. Chander will be responsible for project leadership throughout the product development process.
Curis Strengthens Leadership Team With Appointments Of Jaye Viner, M.D. As Chief Medical Officer And Tania Chander, Pharm.D. As VP Of Product Development
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts